Overview

Post-Autologous Transplant Maintenance With Isatuximab and Lenalidomide in Minimal Residual Disease Positive Multiple Myeloma

Status:
Not yet recruiting

Trial end date:
2030-12-01

Target enrollment:

Participant gender:

Summary

This is a phase II study where patients will undergo isatuximab and lenalidomide maintenance starting at day 90 (+/-30 days) after Autologous Stem Cell Transplant (ASCT) provided they have achieved at least Partial Response (PR).Patients may have received any number of cycles of induction therapy prior to stem cell transplant.

Phase:

Phase 2

Details

Lead Sponsor:

University of Illinois at Chicago

Treatments:

Lenalidomide